Breast Cancer Drug Hope
News May 25, 2016
Scientists have identified a chemical compound that is highly effective at blocking the growth of breast cancer cells in the laboratory.
The compound – called eCF506 – targets a molecule called Src tyrosine kinase that is required for breast cancer cells to grow and spread.
Drugs that target the same molecule are already being tested in clinical trials. Researchers say eCF506 is different because it is more selective and doesn’t affect other molecules in the cell.
This may mean it will be more effective and have fewer side effects than the other drugs in development but further studies are needed, researchers say.
This candidate drug will need to undergo further preclinical testing before it can be taken forward into clinical trials but these early findings are very promising. Professor Neil Carragher, Head of the Edinburgh Cancer Discovery Unit, Cancer Research UK Edinburgh Centre
The study identified the compound using a pioneering approach that uses imaging techniques to directly visualise the effects of candidate drugs on cells.
The team from the University of Edinburgh says the discovery proves that this approach offers a powerful and cost-effective method of discovering new medicines for cancer and other diseases.
The result provides further support for our new drug discovery approach which aims to deliver more effective medicines at reduced costs for patients and healthcare providers. Professor Neil Carragher, Head of the Edinburgh Cancer Discovery Unit, Cancer Research UK Edinburgh Centre
The study, published in the Journal of Medicinal Chemistry, was funded by the Medical Research Council, Wellcome Trust and the commercialisation catalyst Sunergos Innovations.
eCF506 is the first drug candidate of a second generation of Src inhibitors that will not only help to understand the complexity of some cancers but also the development of safer combination therapies. Dr Asier Unciti-Broceta, Cancer Research UK Edinburgh Centre
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Simple Sugar Prevents Neurodegeneration in Lysosomal Storage DiseaseNews
New therapeutic approach may one day delay neurodegeneration typical of a disease called mucopolysaccharidoses IIIB (MPS IIIB)READ MORE